AtriCure Inc (ATRC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AtriCure Inc (ATRC) has a cash flow conversion efficiency ratio of 0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($26.72 Million) by net assets ($476.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AtriCure Inc - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how AtriCure Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ATRC total debt and obligations for a breakdown of total debt and financial obligations.
AtriCure Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AtriCure Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arlo Technologies
NYSE:ARLO
|
0.155x |
|
New Guomai Digital Culture Co Ltd
SHG:600640
|
0.019x |
|
Kimbell Royalty Partners LP
NYSE:KRP
|
0.080x |
|
Precigen Inc
NASDAQ:PGEN
|
-1.122x |
|
Shunsin Technology Holdings Ltd
TW:6451
|
-0.044x |
|
Jiangsu Zijin Rural Commercial Bank Co Ltd
SHG:601860
|
0.019x |
|
Eurocommercial Properties N.V.
AS:ECMPA
|
0.020x |
|
Dole PLC
NYSE:DOLE
|
0.064x |
Annual Cash Flow Conversion Efficiency for AtriCure Inc (2004–2024)
The table below shows the annual cash flow conversion efficiency of AtriCure Inc from 2004 to 2024. For the full company profile with market capitalisation and key ratios, see AtriCure Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $460.97 Million | $12.20 Million | 0.026x | +175.24% |
| 2023-12-31 | $466.17 Million | $4.48 Million | 0.010x | +119.84% |
| 2022-12-31 | $456.75 Million | $-22.14 Million | -0.048x | -70.17% |
| 2021-12-31 | $483.76 Million | $-13.78 Million | -0.028x | +40.88% |
| 2020-12-31 | $412.39 Million | $-19.87 Million | -0.048x | +24.63% |
| 2019-12-31 | $247.34 Million | $-15.81 Million | -0.064x | -282.19% |
| 2018-12-31 | $249.38 Million | $-4.17 Million | -0.017x | +69.86% |
| 2017-12-31 | $161.17 Million | $-8.94 Million | -0.055x | +38.17% |
| 2016-12-31 | $168.44 Million | $-15.12 Million | -0.090x | -113.68% |
| 2015-12-31 | $186.69 Million | $-7.84 Million | -0.042x | +74.22% |
| 2014-12-31 | $132.54 Million | $-21.60 Million | -0.163x | -126.59% |
| 2013-12-31 | $72.60 Million | $-5.22 Million | -0.072x | +53.56% |
| 2012-12-31 | $12.50 Million | $-1.94 Million | -0.155x | -21.75% |
| 2011-12-31 | $15.61 Million | $-1.99 Million | -0.127x | -6267.96% |
| 2010-12-31 | $16.74 Million | $-33.43K | -0.002x | -108.13% |
| 2009-12-31 | $17.09 Million | $419.95K | 0.025x | +112.53% |
| 2008-12-31 | $29.12 Million | $-5.71 Million | -0.196x | +12.45% |
| 2007-12-31 | $36.24 Million | $-8.12 Million | -0.224x | +44.85% |
| 2006-12-31 | $30.69 Million | $-12.47 Million | -0.406x | -130.28% |
| 2005-12-31 | $43.18 Million | $-7.62 Million | -0.176x | -226.84% |
| 2004-12-31 | $-27.33 Million | $-3.80 Million | 0.139x | -- |
About AtriCure Inc
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and li… Read more